This work focuses on the use of antiretroviral agents to prevent the sexual transmission of HIV-1.
Two randomized clinical trials demonstrated that antiretroviral agents provided before exposure to HIV-1 offer substantial protection, ostensibly directly proportional to the concentration of antiretroviral therapy (ART) in the genital secretions. Intense focus on the use of HIV treatment as prevention has led to publication of modeling exercises, ecological studies, and observational studies, most of which support the potential benefits of ART. However, the logistical requirements for successful use of ART for prevention are considerable.
ART will serve as a cornerstone of combination prevention of HIV-1. Continued research will be essential to measure anticipated benefits and to detect implementation barriers and untoward consequences of such a program, especially increases in primary ART resistance.
aDepartment of Epidemiology, USA
bDepartment of Medicine, University of North Carolina, USA
cEshelman School of Pharmacy, USA
dDepartment of Microbiology and Immunology, University of North Carolina, Chapel Hill, North Carolina, USA
Correspondence to Myron S. Cohen, MD, University of North Carolina at Chapel Hill, CB# 7030, 130 Mason Farm Road, 2115 Bioinformatics Building, Chapel Hill, NC 27599-7030, USA Tel: +1 919 966 2536; e-mail: email@example.com